Pharmaceutical Industry
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2024/02/shutterstock_2293046895-800x450.jpg)
Limiting competition in medicines is not an option
Est. 4minEU pharmaceutical legislation is undergoing a major reform which is an opportunity to increase people’s access to medicines, but worryingly some right-leaning political groups want to give even more power to the pharma industry, writes Monique Goyens, Director General of the European Consumer Organisation (BEUC).
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2023/02/Picture-for-Euractiv-800x450.jpg)
How the AI Act could unintentionally impact access to healthcare
Est. 6minMedTech Europe welcomes the efforts made by the European institutions towards giving citizens the confidence to embrace AI solutions. As the negotiations continue, further consideration is needed to ensure safe and innovative patient healthcare delivery.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2022/10/Parente_Pirro_Lorenzin_Cicchetti-800x450.jpeg)
Italy could become a reference point for biotechnology in health care also for its know-how
Est. 9min"We believe that the biotechnology sector, especially in the health sector, can be an element of great value for patients in relation to what is the ability to produce and generate valuable innovation in favour of the well-being and health of people, but it can certainly also be a great driving force for our economic system".
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2021/02/digital-800x450.jpg)
Time to put healthcare at the heart of the digital age
Est. 4minEuropean healthcare stands at a crossroads. It is time to fully embrace AI and digital technology, argues Jan-Philipp Beck.
![Antibiotics](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2015/12/antibiotics.jpeg)
Antimicrobial resistance – a silent pandemic requiring global action now
Est. 5minIf policymakers fail to address the challenge of antimicrobial resistance they risk seeing the rise of a silent pandemic, write Stella Kyriakides and Dr Tedros Adhanom Ghebreyesus.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2020/09/shutterstock_1281497575-1-800x450.jpg)
COVID-19: Time to show citizens that they can count on Europe
Est. 7minEuropean citizens have been exemplary in their fight against COVID 19. They have bravely overcome an acute sanitary threat and paid the high economic, social and psychological price of the lockdown, write a group of European lawmakers.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2020/07/superbugs-800x450.jpg)
Taking action on the global threat of superbugs
Est. 6minCOVID-19 has demonstrated in a quite dramatic way the huge impact of a global threat on public health and economy. While the COVID-19 crisis took us by surprise, our world faces a silent threat that is predictable and preventable, writes Hubertus Von Baumbach, the CEO of pharmaceutical company Boehringer Ingelheim.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2020/05/Vaccine-800x450.jpg)
New health tools for COVID-19
Est. 5minHow to ensure access for all to a coronavirus vaccine should be the priority for world leaders. Dr Bernard Pécoul offers five ideas leaders should consider this week as they aim to raise €7.5 billion to fund vaccine research.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2019/08/ne-800x450.jpg)
What European patients need: a shot of some good old Belgian surrealism
Est. 5minIn art, Belgium is internationally recognised as the land of surrealism, where reality and dreams are intertwined to offer a new perspective on the world. Life sciences is another Belgian specialty and a major historical export product, a group of authors write.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2017/12/shutterstock_420458812-800x450.jpg)
Drugs incentives have saved lives in Europe
Est. 4minWithout strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.
![](https://cdn.statically.io/img/www.euractiv.com/wp-content/uploads/sites/2/2017/08/shutterstock_491623075-800x450.jpg)
EMA relocation should consider the wellbeing of all Europeans
Est. 5minThe competition for the European Medicines Agency is not a horse race but the first concrete, effective decision the EU has to make in the wake of Brexit - and one with long-lasting consequences. A responsible yet ambitious mindset is therefore in order, writes Sandro Gozi.